Title:
PHARMACEUTICAL COMPOSITION COMPRISING INTERLEUKIN-17 INHIBITOR AND TUMOR NECROSIS FACTOR-ALPHA INHIBITOR AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING NEUTROPHILIC LUNG INFLAMMATION DISEASE
Document Type and Number:
WIPO Patent Application WO/2019/124666
Kind Code:
A3
Abstract:
The present invention relates to a pharmaceutical composition comprising an interleukin-17 inhibitor and a tumor necrosis factor-alpha inhibitor as effective ingredients for preventing or treating a neutrophilic lung inflammation disease or a method for screening a therapeutic material for a neutrophilic lung inflammation disease. As a result of research into a change of hematopoiesis in the bone marrow of a neutrophilic asthma mouse model in which a neutrophilic lung inflammatory response had been induced, the present inventors newly revealed G-CSF as a mediator changing the hematopoiesis of the bone marrow, furthermore identified G-CSF production induced by co-stimulation with IL-17 and TNF-α in lung epithelial cells, and experimentally investigated that the hematopoiesis of the bone marrow was normalized by administration of an anti-G-CSF antibody alone or a combination of an anti-IL-17 antibody and an anti-TNF-α antibody in the mouse model, with a resultant therapeutic effect brought about on neutrophilic asthma. Accordingly, the present invention suggests a new therapeutic target for neutrophilic lung inflammation disease, and the IL-17 inhibitor and TNF-α inhibitor according to the present invention are expected to be a new therapeutic modality for neutrophilic lung inflammation disease, which has not been effectively treated with conventional methods.
Inventors:
LEE SEUNG WOO (KR)
KIM YOUNG MIN (KR)
LEE SEUNG WON (KR)
KIM YOUNG MIN (KR)
LEE SEUNG WON (KR)
Application Number:
PCT/KR2018/008879
Publication Date:
August 15, 2019
Filing Date:
August 06, 2018
Export Citation:
Assignee:
POSTECH ACAD IND FOUND (KR)
International Classes:
A61K39/395; A61K39/00; A61P11/00; A61P11/06; G01N33/50; G01N33/68
Domestic Patent References:
| WO2017132457A1 | 2017-08-03 |
Foreign References:
| JP2010053466A | 2010-03-11 | |||
| KR101760512B1 | 2017-07-21 | |||
| KR20170006289A | 2017-01-17 |
Other References:
LI, TIE-JUN ET AL.: "Interleukin-17 antagonist attenuates lung inflammation through inhibition of the ERK1/2 and NF- k B pathway in LPS-induced acute lung injury", MOLECULAR MEDICINE REPORTS, vol. 16, no. 2, 21 June 2017 (2017-06-21), pages 2225 - 2232, XP055630612
Attorney, Agent or Firm:
ISIS IP LAW LLC (KR)
Download PDF: